

The January 2012 Q&A “The Challenges and Concerns Companies Face Pertaining to the US Food and Drug Administration 510(k) Process for Cardiac Biomarkers” moderated by Fred S. Apple and David Morrow (*Clin Chem* 2012;58:31–38; DOI: 10.1373/clinchem.2011.165860) contains an error. The first sentence should read “Cardiac troponin I (cTnI) and T (cTnT) have been internationally recognized as the standard biomarkers for the detection of myocardial injury, the diagnosis of myocardial infarction (MI), and risk stratification of patients presenting with symptoms of acute coronary syndrome (ACS).” The Journal regrets the error.

DOI: 10.1373/clinchem.2012.182949

The January 2012 Mini-Review “Analytical Characteristics of High-Sensitivity Cardiac Troponin Assays” by Fred S. Apple and Paul O. Collinson, for the IFCC Task Force on Clinical Applications of Cardiac Biomarkers (*Clin Chem* 2012;58:54–61; DOI: 10.1373/clinchem.2011.165795) contains two errors. In the second column of Table 2, the 99th percentile CV unit should be ng/L, and the 99th percentile CV value for the Roche Elecsys assay should be 14 (8%). The corrected table is below. The Journal regrets the errors.

Table 2. Analytical characteristics of hs cardiac troponin assays.				
Company/ platform/assay	Cardiac troponin concentration at:			Amino acid residues of epitopes recognized by capture (C) and detection (D) MAbs
	LoD, ^a ng/L	99th Percentile, ng/L (CV) ^b	10% CV concentration, ng/L	
hs-cTnI				
Abbott ARCHITECT ^c	1.2	16 (5.6%)	3.0	C: 24–40; D: 41–49
Beckman Access ^c	2–3	8.6 (10%)	8.6	C: 41–49; D: 24–40
Nanosphere MTP ^c	0.2	2.8 (9.5%)	0.5	C: 136–147; D: MAb PA1010
Singulex Erenna ^c	0.09	10.1 (9.0%)	0.88	C: 41–49; D: 27–41
Siemens Vista ^c	0.5	9 (5.0%)	3	C: 30–35; D: 41–56, 171–190
hs-cTnT				
Roche Elecsys ^d	5.0	14 (8%)	13	C: 136–147; D: 125–131

^a LoD, limit of detection; MTP, microtiter plate.
^b CV at the 99th percentile.
^c Under development and not available for commercial use.
^d Available for use worldwide but not cleared by the US Food and Drug Administration for use in the US.

DOI: 10.1373/clinchem.2012.184135

In the January 2012 Opinion “Troponin Release—Reversible or Irreversible Injury? Should We Care?” by Allan S. Jaffe and Alan H.B. Wu (*Clin Chem* 2012;58:148–150; DOI: 10.1373/clinchem.2011.173070), the following patent information was omitted from the disclosures for A.H.B. Wu: Nov. 23, 2010, #US 7,838,250 B1. The authors regret the omission.

DOI: 10.1373/clinchem.2012.183178